即用型与常规复苏产品在犬失血性休克模型中的比较
研究用6只成年实验犬建立失血性休克模型(平均动脉压<50 mmHg或失血量40%),每只犬依次接受五种复苏产品之一:乳酸林格液/羟乙基淀粉、犬冷全血、新鲜冰冻血浆+浓缩红细胞、犬冻干血浆+血红蛋白氧载体、血红蛋白氧载体/冻干血浆+犬冻干血小板。以休克指数<1判定休克缓解时,FFP/pRBC组(n=5)MAP为83.7±4.5 mmHg,FDP/HBOC+LyoPLT组(n=4)为87.8±2.1 mmHg,均高于冷全血组(n=4)的66.0±13.1 mmHg。HBOC和FDP复苏犬出现一过性肌酐升高;HBOC和FDP产品组白蛋白和碱剩余较LRS/Heta和冷全血组升高(p<0.01)。作者认为即用型血制品组合在休克缓解方面与犬冷全血相当,需进一步研究验证。
要点
- 休克缓解(休克指数<1)时,FFP/pRBC组MAP 83.7±4.5 mmHg(n=5)、FDP/HBOC+LyoPLT组87.8±2.1 mmHg(n=4),均高于冷全血组66.0±13.1 mmHg(n=4)。
- HBOC和FDP复苏犬出现一过性肌酐升高。
- HBOC和FDP产品组白蛋白和碱剩余较LRS/Heta和冷全血组升高(p<0.01)。
- 作者认为即用型血制品组合在休克缓解方面与犬冷全血相当。
- 作者指出需在包含组织损伤成分的出血模型及自然创伤中进一步研究这些组合的可靠性和有效性。
适用人群与场景
- 目的培育的成年实验犬(n=6),麻醉后建立失血性休克模型(平均动脉压<50 mmHg或失血量40%)。
诊断标准与关键阈值
- 失血性休克模型标准:平均动脉压<50 mmHg或失血量40%。
- 休克缓解判定标准:休克指数<1。
处置流程与药物剂量
- 每只犬在失血性休克后接受以下五种复苏产品之一:乳酸林格液和羟乙基淀粉(LRS/Heta)、犬冷全血(CWB)、新鲜冰冻血浆(FFP)和浓缩红细胞(pRBC)、犬冻干血浆(FDP)和血红蛋白氧载体(HBOC)、HBOC/FDP和犬冻干血小板(LyoPLT)。
- 每只犬在出血复苏事件后恢复,然后再次接受出血事件并用不同产品复苏,直至每只犬接受每种产品复苏。
研究设计与关键结果
- 研究类型:犬失血性休克模型实验;样本量:6只成年实验犬;干预:五种复苏产品(LRS/Heta、CWB、FFP/pRBC、FDP/HBOC、HBOC/FDP+LyoPLT),每只犬依次接受所有产品。
- 主要终点结果:休克缓解(休克指数<1)时,FFP/pRBC组(n=5)平均动脉压83.7±4.5 mmHg,FDP/HBOC+LyoPLT组(n=4)87.8±2.1 mmHg,均高于冷全血组(n=4)66.0±13.1 mmHg。
- 关键次要终点:HBOC和FDP复苏犬出现一过性肌酐升高;HBOC和FDP产品组白蛋白和碱剩余较LRS/Heta和冷全血组升高(p<0.01)。
证据类型、等级与局限
- 证据类型:动物实验(犬失血性休克模型)。
- 局限:作者指出需进一步研究以确定这些即用型产品组合在包含组织损伤成分的其他出血模型及自然创伤中的可靠性和有效性。
对床旁实践的改变
- 作者认为即用型血制品组合在休克缓解方面与犬冷全血相当。
- 作者指出需进一步研究以确定这些即用型产品组合在包含组织损伤成分的其他出血模型及自然创伤中的可靠性和有效性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Treatment of severe hemorrhagic shock typically involves hemostatic resuscitation with blood products. However, logistical constraints often hamper the wide distribution of commonly used blood products like whole blood. Shelf-stable blood products and blood substitutes are poised to be able to effectively resuscitate individuals in hemorrhagic shock when more conventional blood products are not readily available.
METHODS: Purpose-bred adult dogs (n = 6) were anesthetized, instrumented, and subjected to hemorrhagic shock (mean arterial pressure <50 mm Hg or 40% blood volume loss). Then each dog was resuscitated with one of five resuscitation products: (1) lactated ringers solution and hetastarch (LRS/Heta), (2) canine chilled whole blood (CWB), (3) fresh frozen plasma (FFP) and packed red blood cells (pRBC), (4) canine freeze-dried plasma (FDP) and hemoglobin-based oxygen carrier (HBOC), or (5) HBOC/FDP and canine lyophilized platelets (LyoPLT). Each dog was allowed to recover after the hemorrhage resuscitation event and was then subjected to another hemorrhage event and resuscitated with a different product until each dog was resuscitated with each product.
RESULTS: At the time when animals were determined to be out of shock as defined by a shock index <1, mean arterial pressure (mmHg) values (mean ± standard error) were higher for FFP/pRBC (n = 5, 83.7 ± 4.5) and FDP/HBOC+LyoPLT (n = 4, 87.8 ± 2.1) as compared with WB (n = 4, 66.0 ± 13.1). A transient increase in creatinine was seen in dogs resuscitated with HBOC and FDP. Albumin and base excess increased in dogs resuscitated with HBOC and FDP products compared with LRS/heta and CWB ( p < 0.01).
CONCLUSION: Combinations of shelf-stable blood products compared favorably to canine CWB for resolution of shock. Further research is needed to ascertain the reliability and efficacy of these shelf-stable combinations of products in other models of hemorrhage that include a component of tissue damage as well as naturally occurring trauma.
参考来源
- Edwards TH, Venn EC, Le TD, et al. Comparison of shelf-stable and conventional resuscitation products in a canine model of hemorrhagic shock. J Trauma Acute Care Surg. 2024. PMID: 38706102. doi:10.1097/TA.0000000000004332
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。